Biofrontera (BFRI) Reports Prelim Q3 Revenue of $8.7-$9M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/19/2026

1. NVDA
2. CRWV
3. SPY
4. IRON
5. EYPT
6. TSLA
7. SLN
8. SLGN
9. STLD
10. CHRD

Go back to Biofrontera (BFRI) Reports Prelim Q3 Revenue of $8.7-$9M

Biofrontera Inc. Announces Preliminary Third Quarter Revenues

October 4, 2023 8:33 AM EDT

Revenues Increased 101% to 108% Over the Prior-Year Quarter

Affirms Guidance for Full-Year Revenue Growth of at Least 25% over 2022

WOBURN, MA / ACCESSWIRE / October 4, 2023 / Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced preliminary unaudited revenues for the three months ended September 30, 2023.

Revenues for the third quarter of 2023 are anticipated to be in the range of approximately $8.7 million to $9.0 million, an increase of approximately 101% to 108% compared with the third quarter of 2022. As a result,... More